Cargando…

Efficacy of anakinra treatment in pediatric rheumatic diseases: Our single-center experience

OBJECTIVES: This study aims to present our experience on anakinra, a recombinant interleukin-1 (IL-1) receptor antagonist, and efficacy results in pediatric rheumatic diseases in our clinic. PATIENTS AND METHODS: Between July 1(st), 2016 and July 1(st), 2020, a total of 33 pediatric patients (18 mal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Demir, Ferhat, Gürler, Eda, Sözeri, Betül
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Turkish League Against Rheumatism 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791547/ https://www.ncbi.nlm.nih.gov/pubmed/36589607 http://dx.doi.org/10.46497/ArchRheumatol.2022.8998

Ejemplares similares

SARS-CoV-2 infection in children with rheumatic disease: Experience of a tertiary referral center
por: Sözeri, Betül, et al.
Publicado: (2021)

Anakinra treatment in patients with Familial Mediterranean Fever: a single-center experience
por: Ugurlu, S, et al.
Publicado: (2015)

Macrophage activation syndrome (MAS) in different pediatric rheumatic disease
por: Gunduz, Zubeyde, et al.
Publicado: (2014)

P01-050 – Anakinra in systemic JIA: single center experience
por: Pardeo, M, et al.
Publicado: (2013)

Evaluation of radiological findings in pediatric patients with COVID-19 in Turkey
por: Kalin, Sevinc, et al.
Publicado: (2021)

Anakinra treatment in multisystemic inflammatory syndrome in children (MIS-C) associated with COVID-19
por: Çaǧlayan, Şengül, et al.
Publicado: (2022)

Outcome results in children with IgA nephropathy: a single center experience
por: Bulut, Ipek Kaplan, et al.
Publicado: (2012)

Anakinra in pediatric acute fulminant myocarditis
por: Maunier, Louise, et al.
Publicado: (2022)

The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience
por: Kostik, Mikhail M., et al.
Publicado: (2022)

Off-label use of rituximab in refractory pediatric rheumatic diseases: a single-center experience
por: Aguiar, Francisca, et al.
Publicado: (2014)

Use of Intravenous Anakinra for Management of Pediatric Cytokine Storm Syndromes at an Academic Medical Center
por: Yang, Lirong, et al.
Publicado: (2023)

Our experience of anti-interleukin 1 therapy
por: Gulez, N, et al.
Publicado: (2015)

Anakinra for the Treatment of COVID-19-Associated Pericarditis: A Case Report
por: Karadeniz, Hazan, et al.
Publicado: (2020)

Subclinical rheumatic heart disease: A single center experience
por: Kayali, Seyma, et al.
Publicado: (2018)

Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)
por: Wehrli, Marc, et al.
Publicado: (2022)

The off-label use of anakinra in pediatric systemic autoinflammatory diseases
por: Maniscalco, Valerio, et al.
Publicado: (2020)

Anakinra and hepatotoxicity in pediatric rheumatology: a case series
por: Martins, Frederico Rajão, et al.
Publicado: (2023)

Anakinra for the treatment of adult secondary HLH: a retrospective experience
por: Naymagon, Leonard
Publicado: (2022)

Comparison of general pediatric ward admissions between the COVID-19 pandemic and pre-pandemic period
por: Güç, Muhammed, et al.
Publicado: (2023)

Efficacy of Anakinra in Pericarditis: A Systematic Review
por: Cheema, Ameer Haider, et al.
Publicado: (2022)

Efficacy of anakinra on rebound of multisystem inflammatory syndrome
por: Brisca, Giacomo, et al.
Publicado: (2022)

Efficacy of Anakinra Treatment in two Moroccan Patients With Mevalonate Kinase Deficiency
por: Souali, Manal, et al.
Publicado: (2023)

Clinical outcomes and safety of anakinra in the treatment of multisystem inflammatory syndrome in children: a single center observational study
por: Dizon, Brian L.P., et al.
Publicado: (2023)

PReS-FINAL-2313: Clinical experiences of therapy in pediatric patients with Behcet uveitis, singe center study
por: Sozeri, B, et al.
Publicado: (2013)

Evaluation of familial mediterranean fever patients: a single center experience
por: Gulez, P, et al.
Publicado: (2015)

Anakinra utilization in refractory pediatric CAR T-cell associated toxicities
por: Diorio, Caroline, et al.
Publicado: (2022)

Anakinra (Kineret) in psoriasis and psoriatic arthritis: a single-center, open-label, pilot study
por: Gibbs, A, et al.
Publicado: (2005)

PW03-018 – Efficacy of Anakinra in recurrent pericarditis
por: Finetti, M, et al.
Publicado: (2013)

Perinatal manifestation of mevalonate kinase deficiency and efficacy of anakinra
por: Peciuliene, Skaiste, et al.
Publicado: (2016)

Methylprednisolone/infliximab/anakinra: Lack of efficacy: case report
Publicado: (2021)

Anakinra/dexamethasone/etoposide: Lack of efficacy: case report
Publicado: (2021)

Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience
por: Kavrul Kayaalp, Gülşah, et al.
Publicado: (2023)

7.3 Successful use of anakinra, a soluble IL-1 receptor antagonist, in pediatric rheumatic diseases associated macrophage activation syndrome/reactive hemophagocytic lymphohistiocytosis
por: Miettunen, PM, et al.
Publicado: (2008)

Evaluation of Children with Acute Rheumatic Fever: A Single-Center Experience
por: Güneş, Ahmet, et al.
Publicado: (2022)

Evaluation of foreign body aspiration cases in our pediatric intensive care unit: Single-center experience
por: Aslan, Nagehan, et al.
Publicado: (2019)

Characteristics of Giant Cell Tumor of the Bone in Pediatric Patients: Our 18-Year, Single-Center Experience
por: Kim, Woo-Jong, et al.
Publicado: (2021)

Uncharted waters: mesenchymal stem cell treatment for pediatric refractory rheumatic diseases; a single center case series
por: Wong, Stephen C., et al.
Publicado: (2021)

Anakinra treatment in patients with systemic-onset juvenil idiopathic arthritis: “The Valencia Experience”
por: Marvillet, I, et al.
Publicado: (2011)

Pediatric Acute Mastoiditis: Our Experience in a Tertiary Care Center
por: Shrestha, Inku B, et al.
Publicado: (2021)

Anakinra treatment for refractory cerebral autoinflammatory responses
por: Jang, Yoonhyuk, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j6q9nl22qrq4gbhsobjc0g563d